Dunad Therapeutics and Novartis enter partnership to develop protein therapies
November 2, 2021Manufacturing and Production
Biopharmaceutical company Dunad Therapeutics (Dunad) has annouced that it has entered into a strategic collaboration with Novartis, to develop orally …
FDA approve Novartis’ Scemblix to treat leukaemia
November 2, 2021Manufacturing and Production
Novartis have announced that the FDA approved Scemblix® (asciminib) for the treatment of chronic myeloid leukaemia (CML) in two distinct …
Skin patch COVID vaccine may prove more effective than injections
November 1, 2021Sales and Marketing
A COVID vaccine skin patch is on course for its first human trial by the University of Queensland in partnership …
China says US COVID origins report lacks credibility
November 1, 2021Sales and Marketing
A US intelligence report saying it was plausible that COVID-19 originated in a Wuhan laboratory has been deemed unscientific and …
FDA issue Pfizer vaccine emergency clearance for children, and delay Moderna
November 1, 2021Sales and Marketing
The FDA has informed Moderna that it needs more time to review the company’s COVID vaccine in children aged 12 …
Study reveals high efficacy of Sputnik V in protecting aged 60+ against COVID
November 1, 2021Sales and Marketing
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) has announced the results of a real world study by …
Gilead collaborate with Merck for first-line triple negative breast cancer trial
October 29, 2021Medical Communications
Gilead Sciences announced that it has entered into a clinical trial collaboration and supply agreement with MSD (known as Merck …
Fluvoxamine effective in reducing hospitalisation in COVID-19 patients
October 29, 2021Medical Communications
A Brazilian study has assessed the effect of early treatment with fluvoxamine on the risk of emergency care and hospitalisation …
FDA approve Susvimo for wet age-related macular degeneration
October 29, 2021Medical Communications
Genentech have announced that Susvimo, previously known as the port delivery system, is the fist wet age-related macular degeneration (AMD) …
XBiotech to launch novel therapy for stroke patients in US
October 29, 2021Medical Communications
Clinical stage biopharmaceutical company, XBiotech, plans to test its new True Humanâ„¢ antibody therapy for reducing brain injury after stroke, …
Angel Pharmaceuticals receives IND approval for Phase 1/1b Inhibitor in China
October 28, 2021Business Services
Angel Pharmaceuticals has received approval for their IND application, from the Center for Drug Evaluation (CDE) of the China National …
Serial radiation therapy safe as alternative treatment for kidney cancer
October 28, 2021Business Services
The University of Texas MD Anderson Cancer Center has reported that Serial radiation therapy as monotherapy is a safe and …
First long-acting HIV-treatment to be distributed in European countries
October 28, 2021Business Services
ViiV Healthcare, the global specialist HIV company, have presented positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first …
FDA approves Phase II clinical trial of combination treatment for COVID-19
October 28, 2021Business Services
The FDA has approved Vitti Labs’ Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination …
Plan C COVID strategy being discussed by government
October 27, 2021Research and Development
An advisor to the Department of Health told MPs a ‘Plan C’ has been mentioned in Government discussions, should the …
Quell Therapeutics receives CTA approval to begin first clinical trial with a multi-modular engineered treg cell company
October 27, 2021Research and Development
The MHRA has approved Quell Therapeutics’ first clinical trial for its lead cell therapy candidate QEL-001. This approval paves the …
Study finds link between COVID-19 infection and neurological complications
October 27, 2021Research and Development
A study conducted by Nature Medicine has revealed an increased risk of Guillain-Barre Syndrome (GBS) and Bell’s palsy following a …
FDA and EMA approve Novartis’ treatment for follicular lymphoma patients
October 27, 2021Research and Development
The FDA and EMA have accepted Novartis’ Supplemental Biologics License Application (sBLA) and Type II Variation for KymriahⓇ in patients …
NIHR funds COVID-19 antiviral trial
October 26, 2021Manufacturing and Production
The National Institute for Health research has awarded funding to the University of Oxford, working with several other UK universities, …
CHMP begins rolling review of COVID oral antiviral
October 26, 2021Manufacturing and Production
The EMA’s human medicine’s committee (CHMP) has initiated a rolling review of the investigational antiviral drug molnupiravir for the treatment …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
